metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	atezolizumab alone
	IMvigor-130 (At-arm B vs Ch-armC), 2020 Lancet 2020; 395:1547-1557 NCT02807636	RCT	mUC - L1 - all population	atezolizumab (B)	chemotherapy (C) gemcitabine plus platine	patients with untreated locally advanced or metastatic urothelial carcinoma	360 / 400	some concern	inconclusive	inconclusive 2 % increase in deaths (OS) (PE) statistically significant 62 % decrease in objective responses (ORR)
versus placebo plus SoC
	atezolizumab plus SoC
	IMvigor-130 (At-arm A vs Pl-arm C), 2020 Lancet 2020; 395:1547-1557 NCT02807636	RCT	mUC - L1 - all population	atezolizumab (A) plus gemcitabine and platine	placebo (C) plus gemcitabine and platine	patients with untreated locally advanced or metastatic urothelial carcinoma	451 / 400	some concern	conclusif	inconclusive 17 % decrease in deaths (OS) (PE) demonstrated 18 % decrease in progression or deaths (PFS) (PE)